Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Recruiting · NCT07101094
Conditions: Schizophrenia
At a glance
- Research payments reported, 2025
- $20,550
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 300
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- xanomeline and trospium chloride (X/T) therapy (drug)
- Dates
- Started 2025-09-22; completion 2029-05-14
- Results posted
- Not yet
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $20,550 in research payments for this study in 2025 (1 payments).
Products named: Cobenfy
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Onsite Clinical Solutions, Llc $20,550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.